SCHEINER, BERNHARD
 Distribuzione geografica
Continente #
EU - Europa 27
AS - Asia 25
NA - Nord America 8
Totale 60
Nazione #
SG - Singapore 13
IT - Italia 11
HK - Hong Kong 10
US - Stati Uniti d'America 8
IE - Irlanda 7
AT - Austria 2
FI - Finlandia 2
IN - India 2
NL - Olanda 2
CH - Svizzera 1
DE - Germania 1
GB - Regno Unito 1
Totale 60
Città #
Hong Kong 10
Dublin 7
Singapore 6
Boardman 3
Amsterdam 2
Deiva Marina 2
Helsinki 2
New Delhi 2
Verona 2
Vienna 2
Forno Canavese 1
Islington 1
Mezzomerico 1
Minneapolis 1
Naples 1
Palermo 1
Quinto di Treviso 1
Turin 1
Zurich 1
Totale 47
Nome #
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 14
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 7
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 7
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 6
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 6
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 5
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control 5
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 3
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 3
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 3
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 3
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 3
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 3
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 3
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 3
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 2
Totale 76
Categoria #
all - tutte 1.598
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.598


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202473 16 1 6 1 12 1 10 4 1 2 2 17
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 76